Anti-human CD38-hAtt (hCD38-hAtt) has been shown to reduce the proliferation of leukemia and lymphoma cell lines in vitro, and to inhibit the growth of CD38-expressing xenograft tumors in immunodeficient mice [11]. Here, CD38 is linked to lymphoma.